MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biopharmaceutical company which specializes in the development of novel therapies to restore, treat and prevent inner ear diseases such as hearing loss, tinnitus and vertigo, will present a keynote plenary lecture at the European Histamine Research Society in Kraków, Poland from May 15-18th, 2019. Contrary to typically sedative H1 receptor antagonist antihistamines used in the man

Source link